DexCom earnings beat by $0.03, revenue topped estimates
Medicure Inc. (OTC:MCUJF), a pharmaceutical company, disclosed its intangible assets status in its recent Form 6-K filing with the Securities and Exchange Commission. As of March 31, 2025, the company reported intangible assets, excluding goodwill, with a gross carrying amount of CAD 43,129,000. This figure includes patents and drug approvals valued at CAD 27,724,000, customer lists at CAD 6,296,000, and software at CAD 2,612,000, among others.
The accumulated amortization and impairment losses on these assets totaled CAD 33,775,000, resulting in a net carrying amount for the company’s intangible assets. Specifically, patents and drug approvals had accumulated amortization and impairment losses of CAD 23,657,000, while customer lists and software had CAD 3,979,000 and CAD 539,000, respectively.
Medicure’s goodwill remained stable at CAD 3,375,000. Additionally, the company’s financial statements indicated that all amounts payable related to party transactions with key management personnel stood at zero.
The report also revealed the terms of Medicure’s stock options, with minimum durations set at five years and maximums at ten years. The company emphasized its commitment to transparent reporting and compliance with regulatory requirements.
Investors and stakeholders are encouraged to review the full details of the company’s financial position as disclosed in the SEC filing. Medicure’s focus on maintaining a clear record of its intangible assets reflects its dedication to sound financial practices and accountability in its operations.
This summary is based on Medicure’s SEC Form 6-K filing and provides a snapshot of the company’s intangible assets and related financial information as of the first quarter ending March 31, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.